수막구균 백신 시장 보고서 : 백신 유형, 조성, 백신 혈청형, 유통 채널, 최종사용자 및 지역별(2026-2034년)

The global meningococcal vaccines market size reached USD 4.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 7.8 Billion by 2034, exhibiting a growth rate (CAGR) of 7.01% during 2026-2034. The increasing burden of meningococcal disease, government immunization programs, ongoing technological advancements, and global health security concerns are driving the primarily driving the market growth.

Meningococcal Vaccines Market Trends:

Rising Prevalence of Meningococcal Disease

The rising prevalence of meningococcal disease is a significant factor driving the demand for meningococcal vaccines. For instance, according to the World Health Organization (WHO), from November 2022 to January 2023, around 559 cases of meningitis, including 18 deaths, were recorded from Zinder Region, southeast of Niger, compared to 231 cases reported from November 2021 to January 2022. Meningococcal disease, caused by Neisseria meningitidis bacteria, remains a significant global health concern due to its potential for rapid onset, severity, and outbreaks. The high disease burden drives the demand for effective vaccines. These factors are expected to propel the meningococcal vaccines market in the coming years.

Increasing Awareness Programs

Public health campaigns, healthcare provider education, and community outreach efforts have increased awareness about meningococcal disease and the importance of vaccination. For instance, in August 2021, GSK introduced "Ask2BSure," a public health campaign to encourage parents to check with their child's doctor to see if they have meningitis B immunization. Meningococcal disease, often known as meningitis, is a rare but potentially fatal condition. Enhanced understanding promotes vaccine acceptance and uptake. These factors further positively influence the meningococcal vaccines market forecast.

Government Immunization Programs

Many countries have established routine immunization schedules that include meningococcal vaccines, targeting infants, adolescents, and high-risk groups. For example, according to a November 2022 update from the Government of Western Australia Department of Health, the School-Based Immunization Program (SBIP) would provide Diphtheria-tetanus-pertussis (dTpa), HPV (human papillomavirus), and Meningococcal ACWY vaccines to students beginning 2023. Similarly, in August 2023, the Queensland Government planned to invest US$ 90 million over the next three years to offer free meningococcal B vaccine vaccinations for young children and adults, thereby boosting the meningococcal vaccine systems market revenue.

Global Meningococcal Vaccines Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global meningococcal vaccines market report, along with forecasts at the global, regional, and country levels from 2026-2034. Our report has categorized the market based on vaccine type, composition, vaccine serotype, distribution channel, and end user.

Breakup by Vaccine Type:

• Conjugate
• Polysaccharide
• Subcapsular

According to the meningococcal vaccines market outlook, conjugate vaccines are composed of polysaccharide antigens from the bacterial capsule of Neisseria meningitidis, chemically linked (conjugated) to a carrier protein. While polysaccharide vaccines contain purified polysaccharide antigens derived from the bacterial capsule of Neisseria meningitidis. Moreover, subcapsular vaccines target specific surface proteins or antigens located within the bacterial capsule or outer membrane of Neisseria meningitidis.

Breakup by Composition:

• Mono Vaccines
• Combination Vaccines

According to the meningococcal vaccines market overview, monovalent vaccines are often in demand during outbreaks or localized epidemics caused by specific meningococcal serogroup. Public health authorities may deploy monovalent vaccines to quickly contain outbreaks and prevent further spread of the disease. While combination vaccines that protect against multiple meningococcal serogroups (e.g., MenACWY) are favored for routine immunization schedules. They streamline vaccination programs by reducing the number of injections and clinic visits required to achieve comprehensive protection.

Breakup by Vaccine Serotype:

• MenACWY
• MenB & Manic
• MenC
• MenA
• MenAC
• Others

MenACWY vaccines protect against meningococcal serogroups A, C, W, and Y. While MenB vaccines target meningococcal serogroup B. MenB vaccines are typically recombinant protein-based or outer membrane vesicle (OMV) vaccines. They contain antigens specific to serogroup B, which are distinct in structure from serogroups A, C, W, and Y. Moreover, MenAC vaccines target meningococcal serogroups A and C. Apart from this, MenA vaccines specifically target meningococcal serogroup A. These are typically monovalent vaccines containing polysaccharide antigens from serogroup A Neisseria meningitidis. Furthermore, MenACWY-DT vaccines combine antigens from meningococcal serogroups A, C, W, and Y.

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Institutional Sales
• Others

Hospitals often administer meningococcal vaccines to patients admitted for various reasons, including those at higher risk of contracting meningococcal disease due to immunocompromised status or underlying conditions. Hospital pharmacies may provide vaccinations to individuals requiring preventive care or as part of travel medicine services. While retail pharmacies cater to the general public, offering convenient access to meningococcal vaccines for individuals seeking preventive healthcare. Apart from this, institutional sales involve large-scale procurement of meningococcal vaccines for public health programs, such as national immunization schedules targeting specific age groups or high-risk populations.

Breakup by End User:

• Pediatric
• Adult

Meningococcal vaccines, such as MenACWY, are included in routine childhood immunization schedules in many countries. Vaccination typically begins in infancy and continues through childhood, with doses administered according to national guidelines. While young adults who missed meningococcal vaccination during adolescence may receive catch-up doses, especially before entering college or university. College and university dormitories often require proof of meningococcal vaccination, boosting demand among this age group.

Breakup by Region:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

According to the meningococcal vaccines market statistics, the rising prevalence of meningococcal disease in North America is a primary driver. Meningococcal infections can lead to severe outcomes, including meningitis and sepsis, which have spurred vaccination efforts. While stringent healthcare policies and regulations in Europe support the adoption and inclusion of meningococcal vaccines in national immunization schedules. This regulatory environment provides stability and encourages vaccine development and distribution. Apart from this, the Asia Pacific region has seen an increase in the incidence of meningococcal disease, prompting higher demand for vaccines.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• GlaxoSmithKline Plc
• Hualan Biological Engineering Inc.
• Incepta Pharmaceuticals Limited
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Ltd.
• Walvax Biotechnology Co. Ltd.

Key Questions Answered in This Report

• How has the global meningococcal vaccines market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global meningococcal vaccines market?
• What are the key regional markets?
• What is the breakup of the market based on the vaccine type?
• What is the breakup of the market based on the composition?
• What is the breakup of the market based on the vaccine serotype?
• What is the breakup of the market based on the distribution channel?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global meningococcal vaccines market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Meningococcal Vaccines Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Vaccine Type

• 6.1 Conjugate
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Polysaccharide
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Subcapsular
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Composition

• 7.1 Mono Vaccines
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Combination Vaccines
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Vaccine Serotype

• 8.1 MenACWY
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 MenB & Manic
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 MenC
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 MenA
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 MenAC
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Others
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospital Pharmacies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Retail Pharmacies
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Institutional Sales
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by End User

• 10.1 Pediatric
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Adult
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 GlaxoSmithKline Plc
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Hualan Biological Engineering Inc.
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
  • 16.3.3 Incepta Pharmaceuticals Limited
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
  • 16.3.4 Novartis AG
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 Pfizer Inc.
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 Financials
    • 16.3.5.4 SWOT Analysis
  • 16.3.6 Sanofi S.A.
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 Financials
    • 16.3.6.4 SWOT Analysis
  • 16.3.7 Serum Institute of India Ltd.
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
  • 16.3.8 Walvax Biotechnology Co. Ltd.
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials